Bhadresh Shah, MD
Pulmonary Disease · Sugar Land, TXNPI 1770555682
Payments from drug & device makers
Across 229 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$964
- Mylan Specialty L.p.$722
- Insmed, Inc.$390
- Takeda Pharmaceuticals U.S.A., Inc.$295
- Inogen, Inc.$133
- plus $838 from 25 others
What the payments were for
- Consulting fees$2,35038%
- Speaking & faculty fees$72212%
- Food & beverage$2,89147%
- Education$1522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $2,772 |
| GSK | 123 | $964 |
| Mylan Specialty L.p. | 1 | $722 |
| Insmed, Inc. | 20 | $390 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $295 |
| Inogen, Inc. | 6 | $133 |
| Eisai Inc. | 6 | $110 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Sanofi | 3 | $70 |
| Sunovion Pharmaceuticals Inc. | 8 | $68 |
| Pfizer | 3 | $56 |
| Viatris Specialty LLC | 3 | $47 |
| Sanofi Pasteur Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 1 | $41 |
| Amgen | 1 | $34 |
| AbbVie | 2 | $27 |
| Hikma Pharmaceuticals USA | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| 3b Medical, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| Optinose US, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| United Therapeutics Corporation | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,115 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,382 | $1,258,331 |
| OfevNintedanib Esylate | 25 | $352,797 |
| OpsumitMacitentan | 20 | $258,515 |
| Breo ElliptaFluticasone/Vilanterol | 360 | $219,432 |
| AdempasRiociguat | 13 | $179,701 |
| Dupixent PenDupilumab | 40 | $151,983 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 142 | $117,653 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $84,532 |
| Spiriva RespimatTiotropium Bromide | 90 | $73,110 |
| EliquisApixaban | 60 | $71,198 |
| Spiriva HandihalerTiotropium Bromide | 57 | $45,152 |
| Incruse ElliptaUmeclidinium Bromide | 76 | $36,262 |
| Ambrisentan | 12 | $33,991 |
| Arnuity ElliptaFluticasone Furoate | 74 | $25,462 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $18,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $964 | $1,539,4881,892 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,772 | $133,394186 claims |
| PfizerEliquis, Paxlovid | $56 | $73,98683 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $41 | $12,17534 claims |
| Eisai Inc.Dayvigo | $110 | $4,59415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Sugar Land
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.